Pay in 4 interest-free payments of $7.47 Learn more
Ships within 48 hours · Estimated delivery Sep 6 - Sep 11
[9] In summary, while NAD+ Injection is a broadly applicable metabolic therapy, it should not be used by anyone allergic to it, and it is generally avoided in pregnant women, cancer patients, or those with serious chronic diseases, absent compelling medical rationale
Next, its particular therapeutic result on wound healing is decreased bleeding (Stupnisek et al., 2012
Administered systemically via subcutaneous injection, GHK-Cu works throughout the body
TB-500 and Thymosin Beta-4 are also prohibited by WADA/USADA under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), applicable at all times both in-competition and out-of-competition TB-500 / Thymosin Beta-4 Clinical Trials: The RGN-352 and RGN-259 Programs RegeneRx Biopharmaceuticals has pursued two clinical development programs for Thymosin Beta-4, providing the most substantial human clinical data available for any TB-500-related compound: RGN-352 (Injectable Thymosin Beta-4 for Cardiac Repair): Phase 1 trial (completed): A double-blind, placebo-controlled study enrolled 40 healthy volunteers across four cohorts of 10 subjects each, testing escalating dose levels of intravenous Thymosin Beta-4 administered daily over 14 days
US$ 24.93
US$ 25.51
US$ 26.23
US$ 26.66
US$ 20.46
